NCT06524609View on ClinicalTrials.gov

EGCG for the Prevention and Treatment of TIPN

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

January 30, 2025

Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
DRUG

Epigallocatechin-3-Gallate

After determining the optimal dose, the efficacy of EGCG was compared with that of a control group (75% alcohol).

DRUG

Alcohol

After determining the optimal dose, the efficacy of EGCG was compared with that of a placebo control group (75% alcohol).

Trial Locations (1)

250117

RECRUITING

Shandong First Medical University Affiliated Cancer Hospital (Shandong Academy of Medical Sciences), Jinan

All Listed Sponsors
collaborator

The Fourth People's Hospital of Jinan

UNKNOWN

lead

Han Xi Zhao

OTHER